Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis Free

A previous multicenter study of patients with TP53-mutated myeloproliferative neoplasms showed a significantly shorter survival in chronic phase myelofibrosis (MF-CP) that included primary (PMF) and secondary MF and was mostly based on research-based mutation screening and was not systematically controlled for patients without TP53 mutations (AJH 2025;100:552). The objective of the current study was to examine the prognostic impact of TP53 mutations (VAF ≥2%) that were discovered during clinical NGS testing among consecutive patients with PMF-CP. Impact on overall (OS) and leukemia-free (LFS) survival was analyzed in the context of other genetic risk factors and calculated from the time of mutation detection.

The current retrospective study includes consecutive patients with PMF-CP who underwent clinical NGS testing at the Mayo Clinic between 2015 and 2025. Diagnoses of PMF-CP and leukemic transformation (LT) were retrospectively fitted to be in accordance with the International Consensus Classification criteria (Blood 2022;140:1200). Mutation and cytogenetic analyses were performed according to institutional protocols for clinical use and reported in conformity with international guidelines. OS and LFS analyses were censored for treatment with allogeneic stem cell transplantation (ASCT) and calculated from the date of NGS. Conventional statistical methods were utilized (JMP Pro 17.1.0, SAS Institute, Cary, NC, USA).

A total of 633 patients with PMF-CP underwent clinical NGS testing prior to LT and prior to ASCT (median age 65 years; males 59%). Median interval from initial diagnosis/referral to NGS testing was 2 months; 357 (56%), 392 (62%), and 429 (68%) patients had NGS performed within 3, 6 and 12 months of diagnosis, respectively. Risk distribution according to the dynamic International Prognostic Scoring System (DIPSS; Blood 2010;115:1703) were low (19%), intermediate-1 (44%), intermediate-2 (31%), or high (6%).

TP53 mutations (TP53^MUT) with variant allele frequency (VAF) of ≥2% were detected in 28 (4.4%) patients with a median VAF of 25.3% (range 2.4-85; ICC-defined multihit 43%). Patients with TP53^MUT were more likely to harbor IDH2^MUT (14% vs. 3%; p<0.01), EZH2^MUT (14% vs. 4%; p=0.03), and unfavorable karyotype (36% vs. 19%; p=0.047) and less likely to harbor CALR type 1/like (4% vs. 18%; p=0.02) and SF3B1^MUT (0% vs. 6%; p=0.07). The association with unfavorable karyotype was mainly driven by multihit configuration. No significant associations with clinical features were apparent.

At a median follow-up of 40 months for surviving patients, 157 (25%) deaths, 48 (8%) LTs and 135 (21%) ASCTs were documented. A near-two-fold lower, albeit not statistically significant OS was observed in the presence of TP53^MUT (median 123 vs. 228 months; HR 1.9, 95% CI 0.94-3.7; p=0.074); the difference reached significance for multihit TP53^MUT (median 81 months; HR 3.6, 1.7-7.7; p<0.01) but not for non-multihit TP53^MUT (median not reached; HR 0.7, 0.2-2.8; p=0.6), both compared to TP53^WT (median 228 months). The significant impact of multihit TP53^MUT on OS was confirmed in multivariable analysis (MVA) that included other high molecular risk (HMR) mutations and unfavorable karyotype: multihit TP53^MUT (HR 2.5, 1.1-5.5; p=0.02), SRSF2^MUT (2.4, 1.5-3.8; p<0.01), ASXL1^MUT (1.8, 1.2-2.6; p<0.01), U2AF1^MUT-Q157 (4.8, 2.6-8.6; p<0.01), and absence of CALR type 1/like (4.0, 2.0-7.8; p<0.01); additional prognostic contribution was not evident for unfavorable karyotype (p=0.17), EZH2^MUT (p=0.3), IDH1^MUT (p=0.6), IDH2^MUT (p=0.7), or any other HMR mutation. Multihit TP53^MUT was also associated with inferior LFS (10-year risk 62% vs. 32% for non-multihit TP53^MUT vs. 15% for TP53^WT; p=0.03) but significance was lost during MVA that included SRSF2^MUT, which was the only HMR mutation showing a significant effect on LFS (HR 5.0, 2.5-9.8; p<0.01). Post-ASCT survival among 135 transplanted patients was significantly shorter for patients with multihit TP53^MUT (N=4; median 5 months) vs. those with non-multihit TP53^MUT (N=7; median not reached) vs. patients with TP53^WT (N=124; median not reached) [p=0.02].

The current study implicates multihit TP53^MUT as an HMR mutation-independent prognostic factor for OS in PMF-CP. By contrast, prognosis in PMF-CP patients with non-multihit TP53^MUT was more likely to be influenced by other HMR mutations, as was the case for those with TP53^WT.